India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has regained NYSE American listing compliance. The company received a letter on November 9, 2017, from NYSE Regulation stating that it is currently in compliance with the NYSE American LLC continued listing standards set forth in section 704 of the NYSE American Company Guide. This update came on the heels of IGC’s annual meeting, which took place on November 8, 2017. As noted in this morning’s news release, the company’s listing eligibility will continue to be assessed on an ongoing basis moving forward, as is the case for all listed issuers.
To view the full press release, visit http://cnw.fm/K15hJ
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us
More from CannabisNewsBreaks
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
[email protected]
